Hematology Frontier

At the 5th Annual Meeting of Chinese Alliance for Societies of Hematology (2025 CASH), Professor Ying Wang from the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, presented a detailed summary of the latest research on CAR-T therapy for ALL. Her presentation covered the efficacy and safety of CAR-T therapies targeting various antigens, including CD19, CD22, and dual-target CAR-T approaches, as well as their application in specific patient populations. She also explored the factors influencing CAR-T therapy outcomes and discussed future directions to optimize this treatment for clinical use. Hematology Frontier has compiled the key insights from her presentation.

Published in Blood and presented at ASH 2024, the LUNA 3 study evaluates the efficacy and safety of rilzabrutinib, an oral Bruton Tyrosine Kinase Inhibitor (BTKi), in patients with previously…

Recently published in Blood, the DREPAGREFFE-2 trial provides crucial insights into long-term cognitive and cerebrovascular outcomes in children with sickle cell anemia (SCA) and a history of abnormal cerebral velocities.…

A recent study published in Blood (Volume 144, Supplement 1, November 5, 2024) explores the role of Lactate Dehydrogenase A (LDH-A) in CD8+ T cell differentiation and its impact on…

A study published in Blood on November 5, 2024, reveals how socioeconomic factors influence access to allogeneic hematopoietic cell transplantation (allo-HCT) for acute myeloid leukemia (AML) patients. The findings indicate…

Presented on November 5, 2024, new research highlights the potential of IMA001 as a novel therapeutic approach for Sickle Cell Disease (SCD). The study demonstrated that IMA001 significantly reduced red…

On December 7, 2024, a phase 3 trial published in The New England Journal of Medicine provided compelling evidence on the addition of blinatumomab to chemotherapy in children with newly…

The 66th American Society of Hematology (ASH) Annual Meeting has successfully concluded, bringing together over 30,000 experts and scholars worldwide. Through meticulously curated sessions, the conference provided profound insights into fundamental research, innovative therapies, and disease management in hematology. To highlight the latest developments, Hematology Frontier presents the News of ASH series, offering key takeaways from ASH’s official reports.

The 66th American Society of Hematology (ASH) Annual Meeting has successfully concluded, bringing together over 30,000 experts and scholars worldwide. Through meticulously curated sessions, the conference provided valuable insights into fundamental research, innovative therapies, and disease management in hematology. To distill the essence of ASH and capture the latest advancements in the field, Hematology Frontier launched the News of ASH series, compiling key takeaways from ASH's official reports to present cutting-edge developments and significant discoveries to readers.

The 66th American Society of Hematology (ASH) Annual Meeting has successfully concluded, gathering over 30,000 experts and scholars from around the world. This year’s conference featured numerous carefully curated sessions, providing profound insights into fundamental research, innovative therapies, and disease management in hematology. To highlight the key findings from ASH 2024, Hematology Frontier presents the News of ASH series, offering a concise summary of the latest breakthroughs in the field.